

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Paz EINAT et al

Art Unit: 1634

Application No.: 09/991,630

Conf. No.9969

Examiner:

Filed: November 6, 2001

Washington, D.C.

For: GENES ASSOCIATED WITH MECHANICAL STRESS, EXPRESSION PRODUCTS ...

Atty.'s Docket: EINAT=7C

Date: December 9, 2002

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

Sir:

Transmitted herewith is a [XX] Amendment [ ]

in the above-identified application.

[XX] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[ ] No additional fee is required.

[ ] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[ ] First - \$ 55.00  
[ ] Second - \$ 200.00  
[X] Third - \$ 460.00  
[ ] Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

[ ] First - \$ 110.00  
[ ] Second - \$ 400.00  
[ ] Third - \$ 920.00  
[ ] Fourth - \$ 1440.00

Month After Time Period Set

[ ] Less fees (\$ ) already paid for \_\_\_ month(s) extension of time on .

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ .


[XX] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ 460.00 .

[ ] A check in the amount of \$ is attached (check no. ).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)


By:   
Roger L. Browdy  
Registration No. 25,618

Facsimile: (202) 737-3528  
Telephone: (202) 628-5197

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900



RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EINAT=7C

#11/B  
CD

In re Application of:	)	Conf. No.: 9969
Paz EINAT et al	)	Art Unit: 1634
Appln. No.: 09/991,630	)	Examiner: Frank Lu
Filed: November 6, 2001	)	Washington, D.C.
For: GENES ASSOCIATED WITH	)	December 9, 2002
MECHANICAL STRESS,	)	
EXPRESSION PRODUCTS ...	)	

AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action of August 7, 2002,  
petition for a three-month extension of time and payment being  
attached hereto, please amend as follows:

IN THE CLAIMS

Please delete claims 2-12, 21-27 and 31 without  
prejudice toward the continuation of prosecution thereof in  
one or more continuing applications.

Please amend claim 1 as follows:

1 (Amended). An isolated polypeptide encoded by a  
nucleic acid molecule comprising nucleotides having a sequence  
set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:6, SEQ ID  
NO:20, SEQ ID NO:22, SEQ ID NO:23 or comprising nucleotides



B1